Related references
Note: Only part of the references are listed.PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
Ewa Surmiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
Jang-June Park et al.
NATURE COMMUNICATIONS (2021)
Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction
Damian Muszak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Structure-based screening and validation of potential dengue virus inhibitors through classical and QM/MM affinity estimation
Marawan Ahmed et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2019)
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Aravindhan Ganesan et al.
SCIENTIFIC REPORTS (2019)
CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy
Bartosz Szostak et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Molecules in cancer immunotherapy: benefits and side effects
Adrian C. Bateman
JOURNAL OF CLINICAL PATHOLOGY (2019)
Cancer immunotherapy: challenges and clinical applications
An-Liang Xia et al.
JOURNAL OF MEDICAL GENETICS (2019)
Shedding Light on Important Waters for Drug Design: Simulations versus Grid-Based Methods
Denis Bucher et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2018)
Intriguing role of water in protein-ligand binding studied by neutron crystallography on trypsin complexes
Johannes Schiebel et al.
NATURE COMMUNICATIONS (2018)
Adverse effects and radiological manifestations of new immunotherapy agents
Yen Zhi Tang et al.
BRITISH JOURNAL OF RADIOLOGY (2018)
Small-molecule antagonists of the immune checkpoint pathways: concept to clinic
Pottayil G. Sasikumar et al.
FUTURE MEDICINAL CHEMISTRY (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
When theory meets experiment: the PD-1 challenge
Marawan Ahmed et al.
JOURNAL OF MOLECULAR MODELING (2017)
Crowding in Cellular Environments at an Atomistic Level from Computer Simulations
Michael Feig et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2017)
NS5A inhibitors for the treatment of hepatitis C infection
Stefano Gitto et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Testing inhomogeneous solvation theory in structure-based ligand discovery
Trent E. Balius et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak et al.
STRUCTURE (2017)
Mechanism of immune evasion in breast cancer
Mozhi Wang et al.
ONCOTARGETS AND THERAPY (2017)
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
Lukasz Skalniak et al.
ONCOTARGET (2017)
Coinhibitory Receptor expression and immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic viral infections and Cancer
Isobel S. Okoye et al.
FRONTIERS IN IMMUNOLOGY (2017)
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Fei Zhang et al.
CELL DISCOVERY (2017)
The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study
Marawan Ahmed et al.
BIOCHEMISTRY (2017)
Calculating Water Thermodynamics in the Binding Site of Proteins - Applications of WaterMap to Drug Discovery
Daniel Cappel et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
Edward Harder et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2016)
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?
Dean G. Brow et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)
Tryfon Zarganes-Tzitzikas et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
Extreme Gradient Boosting as a Method for Quantitative Structure-Activity Relationships
Robert P. Sheridan et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2016)
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
L. Marthey et al.
JOURNAL OF CROHNS & COLITIS (2016)
AutoDock-GIST: Incorporating Thermodynamics of Active-Site Water into Scoring Function for Accurate Protein-Ligand Docking
Shota Uehara et al.
MOLECULES (2016)
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry
Marawan Ahmed et al.
ACS INFECTIOUS DISEASES (2016)
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
Samuel Genheden et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
Abhisek Swaika et al.
MOLECULAR IMMUNOLOGY (2015)
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak et al.
STRUCTURE (2015)
A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes
Khaled H. Barakat et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2015)
Targeting Protein-Protein Interaction by Small Molecules
Lingyan Jin et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
Beyond the Scope of Free-Wilson Analysis. 2: Can Distance Encoded R-Group Fingerprints Provide Interpretable Nonlinear Models?
Mats Eriksson et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Thermodynamics of Water in an Enzyme Active Site: Grid-Based Hydration Analysis of Coagulation Factor Xa
Crystal N. Nguyen et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2014)
Targeting the Small- and Intermediate-Conductance Ca2+-Activated Potassium Channels: The Drug-Binding Pocket at the Channel/Calmodulin Interface
Meng Cui et al.
NEUROSIGNALS (2014)
A Protein Data Bank Survey Reveals Shortening of Intermolecular Hydrogen Bonds in Ligand-Protein Complexes When a Halogenated Ligand Is an H-Bond Donor
Jaroslaw Poznanski et al.
PLOS ONE (2014)
Beyond the Scope of Free-Wilson Analysis: Building Interpretable QSAR Models with Machine Learning Algorithms
Hongming Chen et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
G. Madhavi Sastry et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2013)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Identification of Protein Interactions Involved in Cellular Signaling
Jukka Westermarck et al.
MOLECULAR & CELLULAR PROTEOMICS (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Contributions of water transfer energy to protein-ligand association and dissociation barriers: Watermap analysis of a series of p38 MAP kinase inhibitors
Robert A. Pearlstein et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2013)
Cancer Immunotherapy Current Status and Future Directions
Fumito Ito et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2013)
A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy
Minying Zhang et al.
CLINICAL CANCER RESEARCH (2012)
Grid inhomogeneous solvation theory: Hydration structure and thermodynamics of the miniature receptor cucurbit[7]uril
Crystal N. Nguyen et al.
JOURNAL OF CHEMICAL PHYSICS (2012)
MMPBSA.py: An Efficient Program for End-State Free Energy Calculations
Bill R. Miller et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2012)
Navitoclax (ABT-263) Reduces Bcl-xL-Mediated Chemoresistance in Ovarian Cancer Models
Maureen Wong et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Identification of the functional binding pocket for compounds targeting small-conductance Ca2+-activated potassium channels
Miao Zhang et al.
NATURE COMMUNICATIONS (2012)
The role of the PD-1 pathway in autoimmunity and peripheral tolerance
Brian T. Fife et al.
YEAR IN IMMUNOLOGY (2011)
Autoimmunity associated with immunotherapy of cancer
Sally M. Amos et al.
BLOOD (2011)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fraser F. Fleming et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A dimeric structure of PD-L1: functional units or evolutionary relics?
Yong Chen et al.
PROTEIN & CELL (2010)
Langevin thermostat for rigid body dynamics
Ruslan L. Davidchack et al.
JOURNAL OF CHEMICAL PHYSICS (2009)
Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization
Julien Michel et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Predicting kinase selectivity profiles using free-Wilson QSAR analysis
Simone Sciabola et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2008)
Immunotherapy of autoimmunity and cancer: the penalty for success
Rachel R. Caspi
NATURE REVIEWS IMMUNOLOGY (2008)
Characterization of protein-protein interfaces
Changhui Yan et al.
PROTEIN JOURNAL (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Protein-protein interaction inhibitors: Small molecules from screening techniques
Steven Fletcher et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
The Amber biomolecular simulation programs
DA Case et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
Macromollecullar recognition
C Deremble et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2005)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Share Paper
